Worldwide, hepatitis B virus is the major risk factor for hepatocellular carcinoma (HCC), owing to its high prevalence in the developing world. Hepatitis B virus vaccination programs have and will ...

Disparities in liver cancer risk and outcomes in the LGBTQ community: A literature review. Non-contrast MRI as a surveillance tool for recurrent hepatocellular carcinoma after curative treatment: A ...

Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have ...

This study investigated the long-term prognosis and clinical course of patients who survived for more than 5 years after hepatocellular carcinoma (HCC) diagnosis.This retrospective cohort study used ...

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

A newly developed nomogram predicts preoperative microvascular invasion in patients with HCC, improving surgical planning and outcomes.

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

Announcing a new publication for Acta Materia Medica journal. Icaritin (ICA) is a prenylflavonoid natural product extracted from plants of the Epimedium genus.

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...